Action 1228 CANBRIDGE PHARMACEUTICALS INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues CANbridge Pharmaceuticals Inc.

Actions

1228

KYG1821D1097

Marché Fermé - Hong Kong S.E.
Autres places de cotation
 10:08:49 06/05/2024 		Varia. 5j. Varia. 1 janv.
0,445 HKD -1,11% Graphique intraday de CANbridge Pharmaceuticals Inc. +7,23% -55,05%
22/04 CANbridge Pharmaceuticals Inc. annonce les résultats de l'essai clinique de phase II du CAN008 pour le traitement du glioblastome multiforme CI
28/03 CANbridge Pharmaceuticals Inc. annonce ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Canbridge Pharmaceuticals Shelves Glioblastoma Drug After Phase II Clinical Trials
CANbridge Pharmaceuticals Inc. Announces Results of CAN008 Phase II Clinical Trial for the Treatment of Glioblastoma Multiforme
CANbridge Pharmaceuticals Inc. Announces Change of Principal Place of Business in Hong Kong, Effect from April 15, 2024
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CANbridge and PUMCH announced the establishment of PUMCH, CANbridge Genetic Defect Rare Disease Innovation and Translation Base
CANbridge Pharmaceuticals Grants Share Options, Restricted Shares
CANbridge Pharmaceuticals Inc. Announces Resignation of Derek Paul Di Rocco as Non-Executive Director and A Member of the Nomination and Corporate Governance Committee
CANbridge Pharmaceuticals - Foundation consolidated over time and for a rosy future, 2023 China Conference on Rare Diseases closed successfully
CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress
CANbridge Pharmaceuticals Inc. to Present Fabry Disease Gene Therapy Abstract At Esgct 30Th Annual Congress
CANbridge Announces NDA Acceptance of CAN108 for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
CANbridge Announces NDA Acceptance of CAN108 (®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis by China's National Medical Products Administration
CANbridge Announces Full Enrollment Reached in the Core Part of the CAN103 Phase 2 trial for Gaucher Disease in China
Canbridge Pharmaceuticals Inc. Announces Full Enrollment Reached in the Core Part of the Can103 Phase 2 Trial for Gaucher Disease in China
CANbridge Announces Marketing Approval of CAN108 in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
Canbridge Pharmaceuticals Inc. Announces Marketing Approval of Can108 (Maralixibat Chloride Oral Solution /Livmarli®?) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
CANbridge to Participate in Two Investor Conferences in September
CANbridge Pharmaceuticals' H1 Attributable Loss Narrows
CANbridge Pharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023
CANbridge Pharmaceuticals Releases Phase 1B Data for Red Blood Cell Disorder Treatment
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 1228
  4. Actualités CANbridge Pharmaceuticals Inc.
  5. Autres langues